If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
582.00    -8.00 (-1.36%)
Bid:
581.00
Ask:
582.00
Spread: 1.00 (0.172%)
Market Cap: £507.07m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Market Update

7 Apr 2020 07:00

RNS Number : 9729I
Victrex PLC
07 April 2020
 

 

 

 

 

 

 

 

7 April 2020

 

Victrex plc - market update

 

 'Solid H1 trading, strong financial position, proactive actions on COVID-19'

Victrex plc, an innovative world leader in high performance polymer solutions, today announces a market update covering trading, its financial position and proactive actions on COVID-19.

H1 trading

Trading for the first half year has been solid and in line with expectations:

· Solid volume growth, including a strong finish in March

· Good growth in Automotive and Medical, with a stable performance in Aerospace, Electronics and Value-Added Resellers, offset by weakness in Energy

· H1 2020 inventory c£100m, with high sales stock across US, Europe and Asia; appropriate raw material inventory in the UK and supply chain functioning well

Strong financial position

Victrex is part of multiple supply chains, many of which are supporting critical applications, for example in Medical. The Group retains a strong balance sheet to maintain customer, supplier and investor confidence and to ensure it has sufficient resources to invest and underpin future growth:

· The Group has facilities of £40m, comprising a committed and undrawn RCF of £20m and a £20m accordion, to October 2024

· Net cash position on 31 March of £42.2m, after payment of FY19 final dividend in February

Whilst Victrex benefits from a net cash position, we are acutely aware of the near-term uncertainty at a macro and end-market level, and have prudently implemented appropriate measures to reduce cost and conserve cash, whilst maintaining strong service levels for customers:

· Capital expenditure for UK debottlenecking programme now deferred to FY 2021

· Other capital programmes limited to essential only expenditure

· Operating cost items being limited to prioritise and support customer related activity

· China capacity investment continuing on plan

Other cash conservation measures will remain under review, which could include future shareholder dividends.

 

 

 

Proactive actions on COVID-19

The safety and well-being of Victrex employees continues to be our highest priority. We established a COVID-19 committee at the start of 2020, with a proactive approach and a range of contingency plans already implemented:

· People: we continue to follow governmental or state guidance wherever we operate

· Customers: we continue to serve customers from home offices, with all of our global employees' homeworking, wherever roles are not production related

· Essential industry: the UK government defines Chemicals as an essential industry with essential workers, with Victrex also having a long-standing history in supporting many critical and "life-sustaining" applications, particularly in Medical

o UK operations: reflecting government guidance and requirements in many "life-sustaining" applications, we are continuing to produce aligned to demand, supplemented by high buffer inventory if required

o US operations: we continue to operate on an ongoing modified basis, defined as being a 'life-sustaining' organisation in several states

· Ventilators: in addition to companies we already serve, we are supplying materials for Ventilators or related equipment to a number of global companies

Outlook

Although trading has remained in line with expectations year-to-date and the third quarter has shown early signs of a solid start, including some normal demand returning across parts of Asia, the macro-economic and end-market outlook over the coming months is very uncertain, particularly for Europe and the US.

It is therefore too early to provide guidance for the remainder of the current financial year. We will continue to produce for essential business, monitoring appropriate guidelines and assessing other cash conservation measures as required.

Victrex will report its interim results on 11 May 2020.

 

About Victrex:

 

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of automotive, aerospace, energy (including manufacturing & engineering), electronics and medical. Every day, millions of people use products and applications which contain our materials - from smartphones, aeroplanes and cars to oil and gas operations and medical devices. With over 40 years' experience, we develop world leading solutions in PEEK and PAEK based polymers, semi-finished and finished parts which shape future performance for our customers and our markets, and drive value for our shareholders. Find out more at www.victrexplc.com or follow us on LinkedIn and Twitter @victrexir

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations & Corporate Communications

+44 (0) 7809 595831

 

Jakob Sigurdsson, Chief Executive

+44 (0) 1253 897700

 

Richard Armitage, Group Finance Director

+44 (0) 1253 897700

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFLFLDSVIRIII
Date   Source Headline
24th Jul 20091:13 pmRNSDirector/PDMR Shareholding
17th Jul 20092:24 pmRNSDirector/PDMR Shareholding
30th Jun 20093:38 pmRNSTotal Voting Rights
18th Jun 20092:57 pmRNSDirector/PDMR Shareholding
18th Jun 20092:37 pmRNSDirector/PDMR Shareholding
3rd Jun 200911:29 amRNSBlocklisting Interim Review
2nd Jun 20093:51 pmRNSHolding(s) in Company
29th May 20091:30 pmRNSTotal Voting Rights
19th May 20094:02 pmRNSDirector/PDMR Shareholding
19th May 20097:00 amRNSHalf Yearly Report
30th Apr 200912:03 pmRNSTotal Voting Rights
17th Apr 20093:13 pmRNSDirector/PDMR Shareholding
15th Apr 200912:05 pmRNSHolding(s) in Company
7th Apr 20097:00 amRNSHalf Year Trading Update
31st Mar 20091:48 pmRNSTotal Voting Rights
30th Mar 200910:46 amRNSHolding(s) in Company
18th Mar 200911:54 amRNSDirector/PDMR Shareholding
4th Mar 20092:18 pmRNSDirector/PDMR Shareholding
2nd Mar 20092:41 pmRNSTotal Voting Rights
18th Feb 20093:41 pmRNSDirector/PDMR Shareholding
17th Feb 20094:45 pmRNSDirector/PDMR Shareholding
11th Feb 200910:41 amRNSResult of AGM
10th Feb 20097:00 amRNSAGM and Interim Management Statement
19th Jan 20092:35 pmRNSDirector/PDMR Shareholding
7th Jan 200911:11 amRNSAnnual Information Update
5th Jan 20093:13 pmRNSAnnual Report and Accounts
5th Jan 20092:07 pmRNSTotal Voting Rights
18th Dec 200812:21 pmRNSDirector/PDMR Shareholding
18th Dec 200810:53 amRNSDirector/PDMR Shareholding
16th Dec 20087:00 amRNSFinal Results
2nd Dec 200810:52 amRNSBlocklisting Interim Review
1st Dec 20083:58 pmRNSHolding(s) in Company
1st Dec 20087:00 amRNSTrading Statement
28th Nov 20082:32 pmRNSTotal Voting Rights
24th Nov 200811:40 amRNSDirector/PDMR Shareholding
21st Nov 20082:47 pmRNSHolding(s) in Company
20th Nov 20084:36 pmRNSHolding(s) in Company
7th Nov 20089:49 amRNSTotal Voting Rights
21st Oct 200812:01 pmRNSDirector/PDMR Shareholding
7th Oct 20087:00 amRNSAnnual Trading Update
30th Sep 20082:57 pmRNSTotal Voting Rights
18th Sep 20083:31 pmRNSDirector/PDMR Shareholding
29th Aug 20081:40 pmRNSTotal Voting Rights
20th Aug 200811:30 amRNSDirector/PDMR Shareholding
31st Jul 20084:15 pmRNSTotal Voting Rights
31st Jul 20087:00 amRNSInterim Management Statement
28th Jul 200812:54 pmRNSBoard Appointments
17th Jul 20083:34 pmRNSDirector/PDMR Shareholding
1st Jul 200810:15 amRNSTotal Voting Rights
20th Jun 20082:27 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.